Drugs / ARO-DIMERPA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07223658 | Dec 2025 → Sep 2026 overdue | hyperlipidemia, combined, 2 | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-DIMERPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07223658 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) injection” NCT07223658 ↗ |